WHAT ELSE CAN DOVATO OFFER YOUR PATIENTS?
*Interactions analysed included those between EACS initial regimens available as a single pill and 43 commonly prescribed non-ARVs as defined by EACS.
Want to hear from the experts, including past webinar recordings?
- European AIDS Clinical Society. Guidelines. Version 11.0. October 2021. Accessed December 17, 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf
- Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non- inferiority TANGO randomized trial. Clin Infect Dis. 2022;ciac036 and suppl 1-18. doi:10.1093/cid/ ciac036
- Llibre JM, Alves Brites C, Cheng CY, et al. Switching to the 2-drug regimen of dolutegravir/ lamivudine (DTG/3TC) fixed-dose combination is non-inferior to continuing a 3-drug regimen through 48 weeks in a randomized clinical trial (SALSA). Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual. Slides OALB0303.
- van Wyk J, Ait-Khaled M, Santos J, et al. Metabolic health outcomes at week 144 in the TANGO study, comparing a switch to DTG/3Tc versus maintenance of TAF-based regimens. Presented at: 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual. Poster PEB164.
- Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naïve adults with HIV-1 infection. AIDS. 2022;36(1):39-48. doi:10.1097/QAD.0000000000003070
- Postel N, Schneeweiss S, Wyen C, et al. Real-world data from prospective URBAN cohort on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany. Presented at: HIV Glasgow 2020: October 5-8, 2020; Virtual. Poster 044.